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Abstract: Obestatin is a 23-amino acid peptide derived from proghrelin, a common prohormone for
ghrelin and obestatin. Previous studies showed that obestatin exhibited some protective and therapeutic
effects in the gut. The aim of our presented study was to examine the effect of treatment with obestatin
on trinitrobenzene sulfonic acid (TNBS)-induced colitis. In rats anesthetized with ketamine, colitis
was induced through intrarectal administration of 25 mg of 2,4,6-trinitrobenzene sulfonic acid (TNBS).
Obestatin was administered intraperitoneally at doses of 4, 8, or 16 nmol/kg, twice per day for four
consecutive days. The first dose of obestatin was given one day before the induction of colitis, and the last
one was given two days after administration of TNBS. Fourteen days after the induction of colitis, rats
were anesthetized again with ketamine, and the severity of colitis was determined. The administration
of obestatin had no effect on the parameters tested in rats without the induction of colitis. In rats with
colitis, administration of obestatin at doses of 8 or 16 nmol/kg reduced the area of colonic damage,
and improved mucosal blood flow in the colon. These effects were accompanied by a reduction in the
colitis-evoked increase in the level of blood leukocytes, and mucosal concentration of pro-inflammatory
interleukin-1β. Moreover, obestatin administered at doses of 8 or 16 nmol/kg reduced histological signs
of colonic damage. The administration of obestatin at a dose of 4 nmol/kg failed to significantly affect the
parameters tested. Overall, treatment with obestatin reduced the severity of TNBS-induced colitis in rats.
This effect was associated with an improvement in mucosal blood flow in the colon, and a decrease in
local and systemic inflammatory processes.
Keywords: colitis; TNBS; ghrelin; obestatin; DNA synthesis; interleukin-1β; colonic blood
flow; myeloperoxidase
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1. Introduction
Obestatin is a 23-amino acid peptide, discovered by Zhang et al. in 2005, and is described as
a ghrelin-associated peptide, derived from the post-translational processing of the preproghrelin
gene [1]. It was isolated from the rat stomach [1–3] and that organ was identified as the major
source of circulating obestatin [1,2,4]. On the other hand, further investigations revealed little or
no immunoreactivity in the stomach is observed in young animals in fetal and neonatal periods in
life [5,6]. Apart from the stomach, obestatin expression was also found in other tissues, such as the
endocrine pancreas, adipose tissue, the lung, liver, skeletal muscle, mammary glands, and the male
reproductive system [7–14].
Initially obestatin was reported to activate the G-protein-coupled receptor, GPR39 [1,15], but
later studies did not confirm that obestatin was a ligand of this receptor [7,16–20]. More recently
Granata et al. described that obestatin may bind to the glucagon-like peptide 1 receptor (GLP-1R) in
adipocytes and pancreatic beta cells [8,21]. However, the specific receptor for obestatin is still unknown.
On the other hand, numerous studies showed that administration of obestatin exhibited biological
effects in various tissues [8,15,22–24]. These data indicated that obestatin receptors must be present in
these tissues.
Previous studies indicated that obestatin potentially suppressed motility of the gastrointestinal
tract [25–27], regulated the secretion of insulin [8,21,28–31], protected against ischemia-reperfusion
injury in various organs [22,23,32], inhibited platelet aggregation [33], prevented H2O2-induced
damage in RGC-5 cells [34], and had multiple other functions in digestive system [35–37]. Moreover,
obestatin possibly reflected and affected some clinical syndromes [38–45].
Previous studies showed that ghrelin—an alternative product of post-translational processing
of preproghrelin—exhibited a protective effect in gastrointestinal mucosa against damage caused
by harmful factors [46–50], and potentially inhibited the development of acute pancreatitis [51–53].
Ghrelin also had a therapeutic effect in the gastrointestinal tract [54]. It accelerated the healing of
oral [55,56], gastric [57], and duodenal [55,57] ulcers, and colonic inflammation [58–62]. Ghrelin also
exhibited a therapeutic effect in animal models of acute pancreatitis [63–66].
In the case of obestatin, there are some reports showing protective and therapeutic effects in the
gastrointestinal tract. Obestatin inhibited the development of cerulein- and ischemia-reperfusion-induced
pancreatitis, as well as reduced its severity and accelerated recovery [67–69]. Granata et al. reported that
obestatin promoted the survival of pancreatic islets [8]. Obestatin increased gastric mucosal blood flow
and cell proliferation, leading to acceleration of healing of gastric ulcers [70]. The determination of ratio
of the serum level of obestatin to ghrelin was proposed as a marker form monitoring the activity of
inflammatory process in inflammatory bowel disease (IBD) [71,72]. Its level was significantly reduced
in patients with celiac disease after one year of a gluten-free diet [73]. Previous studies showed that
administration of obestatin inhibited the development of, and accelerated the healing of colitis induced
by acetic acid [74] or dextran sodium sulfate (DSS) [75]. However, in both these models of colitis,
mucosal damage was the result of a direct deleterious effect of chemicals used on previously healthy
mucosa. These models of colitis allows the study of the protective and therapeutic effect of various
factors, but the mechanism of colonic damage in acetic acid- or DSS-induced colitis only moderately
corresponds to the pathophysiology of mucosal damage observed in IBD.
Trinitrobenzene sulfonic acid (TNBS)-induced colitis leads to a transmural inflammation of
colonic wall, that well-corresponds with morphological features observed in clinical IBD [76–78].
This form of experimental colitis is known and studied for at least two decades [78–80]. TNBS
does not cause intestinal inflammation itself, but it is rather a result of a delayed hypersensitivity
reaction. TNBS haptenizes colonic autologous/microbial proteins, making them immunogenic to the
host’s immune system. In fact, TNBS-induced colitis resembles the hapten-induced model. The Th1
lymphocytes-mediated immune response involves various cytokines, including interleukin-12 (IL-12)
and tumor necrosis factor alpha (TNFα) which serve as effector cytokines, leading to transmural
infiltration and inflammation [81–83]. Therefore, this animal model of colitis was generally considered
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to be the most compatible with pathophysiological mechanism of IBD in humans [78]. For this reason,
we used TNBS-induced colitis in our current study, and the aim of this study was to evaluate the effect
of obestatin administration on the severity of trinitrobenzene sulfonic acid (TNBS)-induced colitis.
2. Results
Figure 1 demonstrates the impact of obestatin on the area of colonic damage in TNBS-induced
colitis. In saline- and obestatin-treated rats with no induced colitis, no mucosal damage was detected.
In saline-treated rats, 14 days after colitis induction, the area of mucosal damage was 34.05 ± 3.01 mm2.
Obestatin given at doses of 4, 8, and 16 nmol/kg diminished the damaged area by 9%, 41%, and 48%,
respectively. The results for doses of 8 and 16 nmol/kg were statistically significant.
No damage was observed in microscopic images of mucosa in the control rats (Figure 2A,B,
Table 1). After the period of 14 days, large lesions reaching the muscular membrane, associated with
moderate or heavy inflammatory cell infiltration, and mild fibrosis were observed in colitis-induced rats
(Figure 2C, Table 1). Obestatin treatment with doses of 4, 8, and 16 nmol/kg reduced the histological
manifestation of colonic damage. Either small or no submucosal lesions were reported in rats treated
with a dose of 8 nmol/kg, and small or moderate inflammatory infiltration, and mild fibrosis were
present (Figure 2D, Table 1).
Table 1. Influence of treatment with obestatin given intraperitoneally at doses of 4, 8, or 16 nmol/kg,
and colitis evoked by rectal enema with trinitrobenzene sulfonic acid (TNBS) on morphological signs
of colonic damage, observed 14 days after induction of colitis.
Groups
Morphological Changes
Grading of Colonic Damage
(0–2)
Inflammatory Infiltration
(0–3)
Depth of Damage
(0–3) Fibrosis (0–3)
Control (NaCl) 0 0 0 0
Obestatin 4 0 0 0 0
Obestatin 8 0 0 0 0
Obestatin 16 0 0 0 0
Colitis (TNBS) + NaCl 2 2 3 1
Colitis + Obestatin 4 1–2 1–2 1 2
Colitis + Obestatin 8 0–1 1 0–1 1
Colitis + Obestatin 16 0–1 1 0–1 1
Numbers represent the predominant histological grading in each group.
In rats without the induction of colitis, administration of obestatin at any dose failed to affect
colonic mucosal blood flow (Figure 3). Induction of colitis significantly reduces mucosal blood flow in
the colon by 51%, and this effect was partly reversed by treatment with obestatin. Obestatin given at
doses of 8 or 16 nmol/kg exhibited similar and statistically significant effects on mucosal blood flow in
rats with colitis. The effect of obestatin given at a dose of 4 nmol/kg was statistically insignificant in
comparison with mucosal blood flow observed in rats treated with NaCl after the induction of colitis
(Figure 3).
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Figure 1. Effect of saline (NaCl) or obestatin given at doses of 4 nmol/kg (OB4), 8 nmol/kg (OB8), or 
16 nmol/kg (OB16), and induction of trinitrobenzene sulfonic acid (TNBS)-induced colitis on the area 
of colon mucosal damage. Mean ± standard error of the mean (SEM). n = 10 in each group of animals. 
a p < 0.05 when compared with control; b p < 0.05 when compared with colitis + NaCl. 
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Figure 2. (A) Representative microscopic image of colonic mucosa observed in control rats without 
colitis; (B) Representative microscopic image of colonic mucosa observed 14 days after 
intraperitoneal (i.p.) treatment with obestatin at a dose of 8 nmol/kg without induction of colitis; (C) 
Representative microscopic image of colonic mucosa observed 14 days after induction of colitis 
evoked by TNBS; (D) Representative microscopic image of colonic mucosa observed 14 days after 
induction of colitis and i.p. treatment with obestatin at a dose of 8 nmol/kg. Hematoxylin and eosin 
stain. Original magnification 400×. 
i r . ff t f s li ( l) r st ti i at doses of 4 n ol/ ( ), l kg ( 8), r
16 l kg (OB16), and induction of trinitrobenzene sulfonic acid (T BS)-induce colitis o t e area
of colon cosal a age. ean standard error of the mean (SE ). n = 10 in each group of animals.
a p < 0.05 when compared with control; b p < 0.05 when compared with colitis + NaCl.
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Figure 1. Effect of saline (NaCl) or obestatin given at doses of 4 nmol/kg (OB4), 8 nmol/kg (OB8), or 
16 nmol/kg (OB16), and induction of trinitrobenzene sulfonic acid (TNBS)-induced colitis on the area 
of colon mucosal damage. Mean ± standard error of the mean (SEM). n = 10 in each group of animals. 
a p < 0.05 when compared with control; b p < 0.05 when compared with colitis + NaCl. 
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Figure 2. (A) Representative microscopic image of colonic mucosa observed in control rats without 
colitis; (B) Representative microscopic image of colonic mucosa observed 14 days after 
intraperitoneal (i.p.) treatment with obestatin at a dose of 8 nmol/kg without induction of colitis; (C) 
Representative microscopic image of colonic mucosa observed 14 days after induction of colitis 
evoked by TNBS; (D) Representative microscopic image of colonic mucosa observed 14 days after 
induction of colitis and i.p. treatment with obestatin at a dose of 8 nmol/kg. Hematoxylin and eosin 
stain. Original magnification 400×. 
Figure 2. (A) Representative microscopic image of colonic mucosa observed in control rats without
colitis; (B) Repr sentative microsc pic image of colonic mucosa observed 14 ays after intraperitoneal
(i.p.) treatment with obestatin at a dose of 8 nmol/kg with ut induction of colitis; (C) Represent tive
microscopic image of colonic mucosa observed 14 days after induction f colitis evoked by TNBS;
(D) Representative microscopic image of colonic mucosa observed 14 days after induction of colitis
and i.p. treatment with obestatin at a dose of 8 nmol/kg. Hematoxylin and eosin stain. Original
magnification 400×.
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Figure 3. Effect of saline (NaCl) or obestatin given at doses of 4 nmol/kg (OB4), 8 nmol/kg (OB8), or 
16 nmol/kg (OB16), and induction of TNBS-induced colitis on mucosal blood flow in the colon. Mean 
± SEM. n = 10 in each group of animals. a p < 0.05 when compared with control; b p < 0.05 when 
compared with colitis + NaCl. 
In control saline-treated animals without the induction of colitis, mucosal DNA synthesis in the 
colon reached a value of 55.2 ± 3.8 dpm/μg DNA (Figure 4). The administration of obestatin at doses 
of 4, 8, and 16 nmol/kg failed to affect DNA synthesis in colonic mucosa in rats without the induction 
of colitis. In saline-treated rats with TNBS-induced colitis, mucosal DNA synthesis in the colon was 
reduced to 33% of the control value. Treatment with obestatin partly reversed the colitis-evoked 
reduction in DNA synthesis in the colonic mucosa. This effect was statistically significant after 
obestatin administered at doses of 8 or 16 nmol/kg (Figure 4). 
In rats without colitis, administration of obestatin at any dose had no effect on the mucosal 
concentration of interleukin-1β (IL-1β) in the colon (Figure 5). The induction of colitis significantly 
increased the mucosal concentration of IL-1β in the colon. As shown in Figure 5, rats with colitis 
demonstrated more than a 10-fold increase in this parameter, 14 days after induction of this 
inflammation. The administration of obestatin at all doses used partly reversed the colitis-evoked 
increase in mucosal concentration of IL-1β, and this effect was statistically significant after obestatin 
administered at doses of 8 or 16 nmol/kg (Figure 5). 
In control rats without colitis treated with saline, white-blood-cell (WBC) count reached a value 
of 7495 ± 1415 per 1 mm3 of blood (Figure 6). The administration of obestatin given at doses of 4, 8, 
and 16 nmol/kg had no significant effect on the number of leukocytes in 1 mm3 of blood in rats 
without TNBS-induced colitis (Figure 6). In rats treated with saline after the induction of colitis, 
almost a two-fold increase in the number of blood leukocytes was observed 14 days after the 
induction. Treatment with obestatin given at doses of 4, 8, and 16 nmol/kg reduced the 
colitis-evoked increase in the number of blood leukocytes. Obestatin administered at doses of 8 or 16 
nmol/kg was statistically significant (Figure 6).  
Obestatin given at doses of 4, 8, and 16 nmol/kg had no effect on mucosal myeloperoxidase 
(MPO) activity in the colon in rats without TNBS-induced colitis (Figure 7). In rats treated with 
saline after the induction of colitis, myeloperoxidase activity in colonic mucosa was increased almost 
two-fold 14 days after the induction. Treatment with obestatin given at doses of 4, 8, or 16 nmol/kg 
reduced the colitis-evoked increase in myeloperoxidase activity in the colonic mucosa. This effect 
was statistically significant after obestatin administered at doses of 8 or 16 nmol/kg (Figure 7). 
Fi re 3. Effect of saline (NaCl) or obestatin given at doses of 4 nmol/kg (OB4), 8 nmol/kg (OB8),
or 16 nmol/kg (OB16), and induction of TNBS-induced colitis on mucosal blood flow in the colon.
Mean ± SEM. n = 10 in each group of anim ls. a p < 0.05 when compared with control; b p < 0.05 hen
co pared ith colitis + aCl.
I control saline-treated animals without the induction of colitis, mucosal DNA synthesis in
the colon reached a value of 55.2 ± 3.8 dpm/µg DNA (Figure 4). The administration of obestatin
at doses of 4, 8, and 16 nmol/kg failed to affect DNA synthesis in colonic mucosa in rats without
the induction of colitis. In saline-treated rats with TNBS-induced colitis, mucosal DNA synthesis
in the colon was reduced to 33% of the control value. Treatment with obestatin partly reversed the
colitis-evoked reduction in DNA synthesis in the colonic mucosa. This effect was statistically significant
after obestatin administered at doses of 8 or 16 nmol/kg (Figure 4).
In rats ithout colitis, ad inistration of obestatin at any dose had no effect on the ucosal
concentration of interleukin-1β (IL-1β) in the colon (Figure 5). The induction of colitis significantly
increased the mucosal concentration of IL-1β in the colon. As shown in Figure 5, rats with
colitis demonstrated more than a 10-fold increase in this parameter, 14 days after induction of this
infla ation. The administration of obestatin at all doses used partly reversed the colitis-evoked
increase in ucosal concentration of IL-1 , and this effect as statistically significant after obestatin
ad inistered at doses of 8 or 16 n ol/kg (Figure 5).
In control rats ithout colitis treated ith saline, hite-blood-cell ( B ) count reached a value
of 7495 ± 1415 per 1 m3 of blood (Figure 6). The administration of obestatin given at doses of
4, 8, and 16 nmol/kg had no significant effect on the number of leukocytes in 1 mm3 of blood in
rats without TNBS-induced colitis (Figure 6). In rats treated with saline after the induction of colitis,
al ost a two-fold increase in the number of blood leukocytes was observed 14 days after the induction.
Treatment with obestatin given at doses of 4, 8, and 16 nmol/kg reduced the colitis-evoked increase in
the number of blood leukocytes. Obestatin administered at doses of 8 or 16 nmol/kg was statistically
significant (Figure 6).
bestatin given at doses of 4, 8, and 16 nmol/kg had no effect on mucosal myeloperoxidase (MPO)
activity in the colon in rats without TNBS-induced colitis (Figure 7). In rats treated with saline after
the induction of colitis, myeloperoxidase activity in colonic mucosa was increased almost two-fold
14 days after the induction. Treatment with obestatin given at doses of 4, 8, or 16 nmol/kg reduced the
colitis-evoked increase in myeloperoxidase activity in the colonic mucosa. This effect was statistically
significant after obestatin administered at doses of 8 or 16 nmol/kg (Figure 7).
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Figure 4. Effect of saline (NaCl) or obestatin given at doses of 4 nmol/kg (OB4), 8 nmol/kg (OB8), or 
16 nmol/kg (OB16), and TNBS-induced colitis on mucosal DNA synthesis in the colon. Mean ± SEM. 
n = 10 in each group of animals. a p < 0.05 when compared with control; b p < 0.05 when compared 
with colitis + NaCl. 
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Figure 5. Effect of saline (NaCl) or obestatin given at doses of 4 nmol/kg (OB4), 8 nmol/kg (OB8), or 
16 nmol/kg (OB16), and TNBS-induced colitis on mucosal concentration of interleukin-1β (IL-1β) in 
the colon. Mean ± SEM. n = 10 in each group of animals. a p < 0.05 when compared with control; b p < 
0.05 when compared with colitis + NaCl. 
Figure 4. Effect of saline ( aCl) or obestatin given at doses of 4 n ol/kg ( B4), 8 n ol/kg (OB8), or
16 n ol/kg (OB16), and TNBS-induced colitis on ucosal D A synthesis in the colon. ean ± SEM.
n = 10 in each group of ani als. a p < 0.05 when co pared with control; b p < 0.05 when co pared
with colitis + NaCl.
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Figure 5. Effect of saline (NaCl) or obestatin given at doses of 4 nmol/kg (OB4), 8 nmol/kg (OB8), or 
16 nmol/kg (OB16), and TNBS-induced colitis on mucosal concentration of interleukin-1β (IL-1β) in 
the colon. Mean ± SEM. n = 10 in each group of animals. a p < 0.05 when compared with control; b p < 
0.05 when compared with colitis + NaCl. 
Figure 5. Effect of saline (NaCl) or obestatin given at doses of 4 nmol/kg (OB4), 8 nmol/kg (OB8),
or 16 nmol/kg (OB16), and TNBS-induced colitis on mucosal co centrati n of interleukin-1β (IL-1β)
in the colon. Mean ± SEM. n = 10 in each gr up of animals. a p < 0.05 when compared with control;
b p < 0.05 when compared with colitis + NaCl.
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Figure 7. Effect of saline (NaCl) or obestatin given at doses of 4 nmol/kg (OB4), 8 nmol/kg (OB8), or 
16 nmol/kg (OB16), and induction of TNBS-induced colitis on myeloperoxidase activity in colonic 
mucosa. Mean ± SEM. n = 10 in each group of animals. a p < 0.05 when compared with control; b p < 
0.05 when compared with colitis + NaCl. 
3. Discussion 
In this study, we investigated the effect of obestatin administration on the severity of 
trinitrobenzene sulfonic acid (TNBS)-induced colitis. We found that intraperitoneal administration 
of obestatin given at doses of 8 or 16 nmol/kg reduced the area of colonic damage, and improved 
mucosal blood flow in the colon. The administration of obestatin at a dose of 4 nmol/kg failed to 
significantly affect the parameters tested. This observation was in agreement with previous reports 
that obestatin at doses of 8 or 16 nmol/kg showed preventive and therapeutic effects on acute 
pancreatitis [67–69], chronic gastric ulcers [70], and some models of colitis [74].  
There are numerous methods available to study cell proliferation. The most reliable assay 
measures cell proliferation through the determination of DNA synthesis. The thymidine 
incorporation assay, as a “gold standard”, is the most commonly used assay [84]. Thymidine labeled 
with tritium (3H-thymidine) is incorporated into new strands of chromosomal DNA during the 
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Figure 7. Effect of saline (NaCl) or obestatin given at doses of 4 nmol/kg (OB4), 8 nmol/kg (OB8), or 
16 nmol/kg (OB16), and induction of TNBS-induced colitis on myeloperoxidase activity in colonic 
mucosa. Mean ± SEM. n = 10 in each group of animals. a p < 0.05 when compared with control; b p < 
0.05 when compared with colitis + NaCl. 
3. Discussion 
In this study, we investigated the effect of obestatin administration on the severity of 
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mucosal blood flow in the colon. The administration of obestatin at a dose of 4 nmol/kg failed to 
significantly affect the parameters tested. This observation was in agreement with previous reports 
that obestatin at doses of 8 or 16 nmol/kg showed preventive and therapeutic effects on acute 
pancreatitis [67–69], chronic gastric ulcers [70], and some models of colitis [74].  
There are numerous methods available to study cell proliferation. The most reliable assay 
measures cell proliferation through the determination of DNA synthesis. The thymidine 
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assay, as a “gold standard”, is the most commonly used assay [84]. Thymidine labeled with tritium
(3H-thymidine) is incorporated into new strands of chromosomal DNA during the synthesis (S) phase
of the cell cycle. Replication of DNA is a necessary step for subsequent cell division.
The current study revealed that application of obestatin in animals without TNBS-induced colitis
had no significant effect on mucosal DNA synthesis in the colon. This leads to the conclusion that, in
animals with normal colonic mucous membranes, obestatin does not stimulate DNA synthesis, and
thus, as it was previously noted, administration of this peptide appears safe, and neither poses a risk of
hyperplasia or hypertrophy [74]. Additionally, administration of obestatin in rats with TNBS-induced
colitis led to a considerable improvement of mucosal DNA synthesis in the colon, which indicated that
in the course of TNBS-induced colitis, obestatin improved cell vitality and increased proliferation to
some extent.
Adequate organ blood flow plays an extremely important role in maintaining mucosal integrity.
Blood circulation supplies the colon with oxygen and HCO3−, removes H+ and CO2, and protects the
mucosa from toxic agents diffusing from the lumen [85,86]. The experimental studies in rat models
showed that exposure of various parts of the digestive tract, such as the oral cavity, esophagus, stomach,
duodenum, and colon, to noxious factors caused no damage or minimal mucosal damage, so long
as sufficient blood flow was maintained [55,57,87–90]. In this study, we observed that intrarectal
administration of TNBS decreased mucosal blood flow in the colon. On the other hand, administration
of obestatin significantly improved mucosal blood flow in the colon of animals with colitis. In contrast,
administration of obestatin in rats without colitis had no effect on mucosal blood flow in the colon.
These observations indicated that obestatin was involved in the improvement of colonic blood flow in
rats with colitis, but this effect seemed to be an indirect influence of obestatin on colonic circulation.
The improvement of colonic blood flow was probably related to the obestatin-evoked reduction
in colonic damage and local inflammation. This observation was supported by previous studies
showing that the relationship between mucosal blood flow and mucosal damage was bidirectional.
An improvement of mucosal blood flow reduces mucosal damage and accelerates mucosal regeneration;
there as, a reduction in mucosal blood flow intensifies mucosal damage [85,86].
White blood cells (WBCs), also called leukocytes, are the cells of the immune system. These cells
participate in the protection of the body against infectious and toxic agents, as well as being involved in
the inflammatory process [91,92]. On the basis of their appearance, WBCs are divided into granulocytes
and agranulocytes. Granulocytes are then divided into neutrophils, eosinophils, and basophils;
whereas agranulocytes include lymphocytes and monocytes. The number of leukocytes in the blood
may vary in physiological and pathological conditions. Physiologically, WBC count rises after food
intake, physical effort, stress, and emotional reactions. In pathological conditions, the main pathological
causes of WBC-count elevation are infection and/or inflammation. Neutrophils are the first cells
recruited to the colon, and their inflammatory response is believed to correspond with disease severity.
Neutrophil-mediated inflammation can be a double-edged sword. In animal models, ablation of
the neutrophil response had both favorable [93,94] and unfavorable consequences [95,96]. Neutrophil
activity itself can lead to immune-mediated damage of host tissues, and therefore, for the best outcome
of colitis therapy, a well-balanced and controlled neutrophil response is preferred. Neutrophils are also
known to reflect the degree of inflammation [97]. Most clinical studies and scoring indices focus on total
WBC count in colitis, and recent studies suggested that neutropenia should be regarded as a risk factor
comparable to leukocytosis [98,99]. A decrease in WBC count debilitates the protective mechanism
against infection and inflammation. In our presented study, WBC count reached a value of almost
8000 per mm3 of blood in control rats treated with saline without colitis. The administration of obestatin
in the doses used had no significant effect on WBC count in rats without colitis. This observation
suggested that doses of obestatin did not affect the immune system in this physiological condition.
Colitis significantly increased WBC count, and the administration of obestatin in these rats reduced
the level of this parameter. In the cases of obestatin given at doses of 8 or 16 nmol/kg, this effect was
statistically significant. These observations indicated that the induction of colitis via TNBS enema
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led to the development of a systemic inflammatory response, and obestatin was able to reduce this
effect. This systemic inflammation was, of course, induced by the local inflammatory process in the
colon, and local inflammation still existed 14 days after induction. It was found upon macroscopic
and microscopic examination of the colon, and manifested as changes in the mucosal colonic IL-1β
concentration, and the activity of MPO.
IL-1β is a member of the IL-1 family, and plays a crucial role in the pathomechanism of
inflammation [100–102]. It is mainly produced by activated macrophages in the form of proproteins,
and is proteolytically processed into its active form by intracellular caspase 1 or extracellular neutrophil
proteases. IL-1β is an important inflammatory mediator involved in a number of diverse cellular
activities, such as cell proliferation, differentiation, and apoptosis [100,103,104]. The fundamental role
of IL-1β depends on the activation of local and systemic pro-inflammatory responses, which lead to
an acute phase of inflammation [101]. It acts directly and indirectly through the stimulation of the
release of other pro-inflammatory factors, such as interleukin-6 (IL-6) and tumor necrosis factor α
(TNFα) [105,106]. Our presented study showed that TNBS-induced colitis led to an increase in IL-1β
concentration in the damaged tissue, and this effect was still observed 14 days after administration of
TNBS. The administration of obestatin had no effect on mucosal concentration of IL-1β in rats without
colitis. In rats with colitis, treatment with obestatin caused a significant decrease in the level of this
pro-inflammatory factor in colonic mucosa.
Since myeloperoxidase (MPO) is released from the granules of neutrophils during inflammatory
response, its activity corresponds with the degree of tissue infiltration by neutrophils [62–64]. In the
presented study, induction of colitis with TNBS caused an increase in mucosal MPO activity, whereas
obestatin treatment partially, but significantly, reversed this effect. This finding provided further
evidence that obestatin exhibits anti-inflammatory effects in the colon. The above observation was
consistent with our previous studies, which pointed to the protective effect of obestatin against acetic
acid-induced colitis, and confirmed its healing properties in this model [74]. These data suggested that
the anti-inflammatory effect of obestatin was independent of a primary course of colitis.
The above findings on the inhibitory effect of obestatin on IL-1β levels, and MPO activity in
colonic mucosa in rats with TNBS-induced colitis indicated that the effect of promoting healing was at
least, in part, associated with the anti-inflammatory properties of obestatin. Moreover, the observation
that obestatin did not affect mucosal IL-1β concentration, and MPO activity in the colon of rats
without induced colitis suggested that obestatin did not disturb the immune system when no signs of
inflammation were present.
As mentioned in the introduction, obestatin and ghrelin are products of the same gene, and are
derived from a common preprohormone [1–3]. The protective and therapeutic effects of ghrelin were
proven in various organs and experimental models [46,47,51,54,56–58,61,63,89]. Obestatin seemed
to present similar effects on the inflammatory processes in the gut [67–70,74,75]. Our presented
study showed that obestatin reduced the severity of TNBS-induced colitis in rats; however, the direct
mechanism of its action remains unclear [1,7,8,15–21].
Inflammatory bowel disease (IBD) is a chronic and relapsing disease, and is an important
clinical problem. IBD is characterized as the chronic dysregulation of the mucosal immune system
in the gastrointestinal tract; however, its pathogenesis is still unclear. To investigate the mechanism,
pathophysiology, and new methods of treatment of IBD, various animal models of experimental colitis
were developed [78,80,107]. TNBS-induced models of colitis, typical for Crohn’s disease, result in
inadequate cell-mediated immune response, and acute Th1 inflammation, which includes a dense
colonic tissue infiltration by cluster of differentiation 4 (CD4) T cells, and the release of numerous
potent pro-inflammatory agents. Clinical manifestations of acute colitis in animals include inconsistent
stool formation, occult, or even bloody diarrhea, loss of body weight, piloerection of fur, decreased
movements of the animals, and death [78].
Our current study showed that intraperitoneal administration of obestatin caused a reduction in
the area of colonic damage, improved mucosal blood flow in the colon, and reduced white-blood-cell
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level, mucosal concentration of pro-inflammatory interleukin-1β, and mucosal activity of MPO, which
accelerated the healing of TNBS-induced colitis. These protective and therapeutic effects of obestatin
were dose-dependent. In conclusions, we can say that administration of obestatin reduces severity of
TNBS-induced colitis, and was apparently associated with an obestatin-induced anti-inflammatory
effect, accompanied by an improved local mucosal blood flow, and increased cell proliferation in
colonic mucosa.
4. Materials and Methods
4.1. Animals and Treatment
Studies were conducted on eighty rats; their weights ranged from 220 to 250 g. The study complied
with the experimental protocol approved by the First Local Committee of Ethics for the Care and Use
of Laboratory Animals in Cracow (permit number 26/2016, released on 20 July 2016). During the
experiments, animals were kept in cages stored at room temperature under a 12 h light–dark cycle.
For 16 h prior to induction of colitis, the animals were fasted with free access to water. Then, water
and food intake were available ad libitum.
The animals were randomly divided into eight experimental groups: (1) control rats without
induction of colitis, and treated intraperitoneally (i.p.) with saline; (2) rats without induction of colitis,
and treated i.p. with obestatin at a dose of 4 nmol/kg; (3) control rats without induction of colitis,
and treated i.p. with obestatin at a dose of 8 nmol/kg; (4) control rats without induction of colitis,
and treated i.p. with obestatin at a dose of 16 nmol/kg; (5) rats with colitis treated i.p. with saline;
(6) rats with colitis treated i.p. with obestatin at a dose of 4 nmol/kg; (7) rats with colitis treated i.p.
with obestatin at a dose of 8 nmol/kg; and (8) rats with colitis treated i.p. with obestatin at a dose of
16 nmol/kg.
Before induction of colitis, rats were fasted for 16 h, and anesthetized with ketamine (50 mg/kg i.p.,
Bioketan, Biowet, Gorzów Wielkopolski, Poland). The colitis was induced by intrarectal administration
of 25 mg of 2,4,6-trinitrobenzene sulfonic acid (TNBS) dissolved in 0.25 mL of 50% ethanol [78,81].
Saline solution was similarly administered to rats without induction of colitis.
Starting 24 h before the rectal enema with saline or TNBS, the rats were treated with saline (groups
1 and 5) or obestatin (groups 2–4 and 6–8) administered i.p., twice per day for 4 consecutive days. Rat
obestatin (Yanaihara Institute, Shizuoka, Japan) was given at doses of 4, 8, or 16 nmol/kg. These doses
were chosen because previous studies showed that obestatin given at doses of 8 and 16 nmol/kg
exhibited strong and repeatable therapeutic effects in the healing of acute pancreatitis, chronic gastric
ulcers, and colitis [67,70,74].
Fourteen days after the induction of colitis, rats were again anesthetized with ketamine
(50 mg/kg i.p., Bioketan, Vetoquinol Biowet, Gorzów Wielkopolski, Poland), and the severity of
colitis was determined.
4.2. Measurement of Colonic Blood Flow, Leukocytes in the Blood, and Colonic Damage
The abdominal cavity was opened, the colon was exposed, and the colonic blood flow was
measured by means of a laser Doppler flowmeter (PeriFlux 4001Master monitor, Perimed AB, Järfälla,
Sweden); the procedure was carried out in accordance with the previously described methodology [90].
The blood flow was measured at five points of the sigmoidal colon, and the main value of the records
was expressed as a percentage of the value recorded in animals from the control group.
After the measurement of colonic blood flow, arterial blood was taken from the abdominal aorta,
and collected in tubes containing ethylenediaminetetraacetic acid (EDTA). The level of leukocytes
(white blood cells—WBC) was determined using the automated hematology analyzer, Sysmex XE 2100
(Sysmex Corporation, Kobe, Japan).
After the measurement of colonic blood flow, and the collection of blood samples, animals were
euthanized via exsanguination. Then, the area of mucosal damage in the colon was measured using a
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computerized planimeter (Morphomat, Carl Zeiss, Berlin, Germany), in accordance with the method
previously described [55].
4.3. Biochemical Analysis
Following the measurements of colonic blood flow and the lesion area, histological examination
of colonic samples, mucosal DNA synthesis (the index of mucosal proliferation), pro-inflammatory
interleukin-1β concentration and myeloperoxidase activity was performed.
4.3.1. Determination of DNA Synthesis in Colonic Mucosa
The role of DNA synthesis in colonic mucosa was determined via measurement of incorporated
tritium-labeled thymidine into DNA, according to the methodology previously described [59,61,108].
Samples of colonic mucosa were incubated at 37 ◦C for 45 min in 2 mL of solution containing
tritium-labeled thymidine ([3H]-thymidine, 20–30 Ci/mmol; Institute for Research, Production and
Application of Radioisotopes, Prague, Czech Republic) with an activity of 8 µCi/mL. The level of
incorporation of labeled thymidine into DNA was determined by measuring 0.5 mL DNA-containing
supernatant in a liquid-scintillation system. The rate of DNA synthesis was expressed as the number
of tritium-atom disintegrations per minute per microgram of DNA (dpm/µg DNA).
4.3.2. Determination of Interleukin-1β Concentration in Colonic Mucosa
The colonic mucosa specimens were homogenized in phosphate buffer at a temperature of 4 ◦C.
Next, the homogenate was centrifuged. The interleukin-1β concentration in the supernatant was
determined using the Rat IL-1β Platinum ELISA kit (Bender MedSystem GmbH, Vienna, Austria).
The value was expressed in ng per g of tissue.
4.3.3. Determination of Myeloperoxidase Activity in Colonic Mucosa
Biopsy samples were homogenized in ice-cold potassium phosphate, and were stored at a
temperature of −60 ◦C until the markings were conducted. Myeloperoxidase activity was assessed
based on a modification of the method described by Bradley et al. [109]. Results, given in units per
gram of tissue, were expressed as a percentage of the value recorded in the control group.
4.4. Histological Examination of the Colon
Samples of the colon were fixed in 10% buffered formaldehyde, and embedded in paraffin.
Paraffin sections were stained with hematoxylin and eosin, and examined by the pathologist
uninformed of the treatment implemented beforehand. The histological grading of colonic damage
(i.e., ulceration, inflammation, depth of the lesion, and fibrosis) were determined using a scale devised
by Vilaseca et al. [110], as previously described in detail [59]. For the histological grading of lesions,
a scale ranging from 0 to 2 was used (0 = no lesions; 1 = small lesions < 3 mm; and 2 = large lesions
> 3 mm). Inflammatory infiltration was graded from 0 to 3 (0 = none; 1 = small; 2 = moderate; and
3 = heavy), and the depth of lesions was assigned numbers from 0 to 3 (0 = no lesions; 1 = lesions
reaching submucosa; 2 = lesions reaching muscularis propia; and 3 = lesions reaching serosa). For the
evaluation of fibrosis, grades from 0 to 2 were applied (0 = none; 1 = mild; and 2 = severe). Moreover,
the occurrence of inflammation of arterial vessels was assessed.
4.5. Statistical Analysis
Results were presented as mean values ± standard error of the mean (SEM). Analysis of variance
was conducted, followed by Tukey’s multiple comparison test, using GraphPad Prism (GraphPad
Software, San Diego, CA, USA). A p-value < 0.05 was considered statistically significant.
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35. Słupecka, M.; Woliński, J.; Herman, A.P.; Ochniewicz, P.; Kornacka, M.K. Biological role of obestatin in
physiology and pathophysiology. Med. Wieku Rozw. 2012, 16, 47–52.
36. Trovato, L.; Gallo, D.; Settanni, F.; Gesmundo, I.; Ghigo, E.; Granata, R. Obestatin: Is It Really Doing
Something? Front. Horm. Res. 2014, 42, 175–185. [CrossRef] [PubMed]
37. Xing, Y.-X.; Yang, L.; Kuang, H.-Y.; Gao, X.-Y.; Liu, H.-L. Function of Obestatin in the Digestive System.
Nutrition 2017, 34, 21–28. [CrossRef] [PubMed]
38. Ren, A.-J.; Guo, Z.-F.; Wang, Y.-K.; Lin, L.; Zheng, X.; Yuan, W.-J. Obestatin, Obesity and Diabetes. Peptides
2009, 30, 439–444. [CrossRef] [PubMed]
39. Zhang, N.; Yuan, C.; Li, Z.; Li, J.; Li, X.; Li, C.; Li, R.; Wang, S.-R. Meta-Analysis of the Relationship between
Obestatin and Ghrelin Levels and the Ghrelin/Obestatin Ratio with Respect to Obesity. Am. J. Med. Sci.
2011, 341, 48–55. [CrossRef] [PubMed]
40. Zou, C.C.; Liang, L.; Wang, C.L.; Fu, J.F.; Zhao, Z.Y. The Change in Ghrelin and Obestatin Levels in Obese
Children after Weight Reduction. Acta Paediatr. 2009, 98, 159–165. [CrossRef] [PubMed]
41. Wali, P.; King, J.; He, Z.; Tonb, D.; Horvath, K. Ghrelin and Obestatin Levels in Children with Failure to
Thrive and Obesity. J. Pediatr. Gastroenterol. Nutr. 2014, 58, 376–381. [CrossRef] [PubMed]
42. Harsch, I.A.; Koebnick, C.; Tasi, A.M.; Hahn, E.G.; Konturek, P.C. Ghrelin and Obestatin Levels in Type 2
Diabetic Patients with and without Delayed Gastric Emptying. Dig. Dis. Sci. 2009, 54, 2161–2166. [CrossRef]
[PubMed]
43. Qi, X.; Li, L.; Yang, G.; Liu, J.; Li, K.; Tang, Y.; Liou, H.; Boden, G. Circulating Obestatin Levels in Normal
Subjects and in Patients with Impaired Glucose Regulation and Type 2 Diabetes Mellitus. Clin. Endocrinol.
2007, 66, 593–597. [CrossRef] [PubMed]
44. Butler, M.G.; Bittel, D.C. Plasma Obestatin and Ghrelin Levels in Subjects with Prader-Willi Syndrome. Am. J.
Med. Genet. 2007, 143A, 415–421. [CrossRef] [PubMed]
45. Liu, W.; Yue, H.; Zhang, J.; Pu, J.; Yu, Q. Effects of Plasma Ghrelin, Obestatin, and Ghrelin/Obestatin Ratio
on Blood Pressure Circadian Rhythms in Patients with Obstructive Sleep Apnea Syndrome. Chin. Med. J.
2014, 127, 850–855. [PubMed]
46. Sibilia, V.; Rindi, G.; Pagani, F.; Rapetti, D.; Locatelli, V.; Torsello, A.; Campanini, N.; Deghenghi, R.; Netti, C.
Ghrelin Protects against Ethanol-Induced Gastric Ulcers in Rats: Studies on the Mechanisms of Action.
Endocrinology 2003, 144, 353–359. [CrossRef] [PubMed]
47. Brzozowski, T.; Konturek, P.C.; Konturek, S.J.; Kwiecień, S.; Drozdowicz, D.; Bielanski, W.; Pajdo, R.;
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